Literature DB >> 28845026

Marked recovery from glucotoxicity of β-cell function after medical nutrition therapy without pharmacotherapy in type 2 diabetic outpatients with extreme hyperglycemia: a pilot retrospective study.

Mitsuyoshi Takahara1, Toshihiko Shiraiwa2, Naoto Katakami3, Taka-Aki Matsuoka3, Iichiro Shimomura3.   

Abstract

We investigated whether glucotoxicity of β-cell function could be eliminated after medical nutrition therapy (MNT) without forced correction of hyperglycemia by anti-diabetic medications including exogenous insulin administration. We analyzed newly diagnosed type 2 diabetic outpatients with hemoglobin A1c (HbA1c) of 10.1 ± 1.5%, who were treated by MNT at least for three months, without any aid of anti-diabetic medications. The β-cell function was calculated as the product of the ΔIns0-120/ΔGlu0-120 and the Matsuda index, where ΔIns0-120/ΔGlu0-120 represents the ratio of the incremental concentrations of insulin to those of glucose during the 0- to 120-min time periods under a 75-g oral glucose tolerance test. After MNT, HbA1c levels were reduced to 7.0 ± 1.0% (p < 0.001). The β-cell function was significantly improved (n = 13; p = 0.001; effect size d = 1.9). Fasting plasma glucose became below 7.0 mmol/l in 57% (8/13), and 120-minute plasma glucose became below 11.1 mmol/l in 43% (6/13). The β-cell function after MNT was significantly correlated with HbA1c levels achieved after MNT (Pearson's correlation coefficient r = -0.62, p = 0.025). In conclusion, the β-cell dysfunction was ameliorated after MNT without glucose-lowering pharmacotherapy in newly diagnosed type 2 diabetic outpatients who presented extreme hyperglycemia.

Entities:  

Keywords:  Glucotoxicity; Medical nutrition therapy; β-cell function

Mesh:

Substances:

Year:  2017        PMID: 28845026     DOI: 10.1507/endocrj.EJ17-0222

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  2 in total

1.  Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes.

Authors:  Mitsuyoshi Takahara; Toshihiko Shiraiwa; Taka-Aki Matsuoka; Kaoru Yamamoto; Yoshifumi Maeno; Yuka Shiraiwa; Yoko Yoshida; Naoto Katakami; Hiroaki Iijima; Hideyuki Katsumata; Kenji Arakawa; Toshio Hashimoto; Iichiro Shimomura
Journal:  Diabetes Metab Syndr Obes       Date:  2020-11-18       Impact factor: 3.168

2.  Improvement of beta-cell function in conjunction with glycemic control after medical nutrition therapy in newly-diagnosed type 2 diabetes mellitus.

Authors:  Mitsuyoshi Takahara; Toshihiko Shiraiwa; Yoshifumi Maeno; Kaoru Yamamoto; Yuka Shiraiwa; Yoko Yoshida; Norio Nishioka; Naoto Katakami; Iichiro Shimomura
Journal:  BMC Endocr Disord       Date:  2022-06-04       Impact factor: 3.263

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.